Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · AYTU BIOPHARMA, INC (AYTU)

Aytu BioPharma Q4 revenue rises 6.4% to $16.1 million; full-year revenue falls 13.3%

Mixed Impact 3 of 5 earnings Written later

Aytu BioPharma reported fiscal 2026 fourth-quarter net revenue of $16.1 million, up 6.4% from $15.1 million a year earlier, and a net loss of less than $0.1 million, versus a $19.8 million loss in the prior-year quarter. For the full year, net revenue fell 13.3% to $57.6 million and the net loss widened to $14.3 million from $13.6 million, while Adjusted EBITDA was negative $3.7 million compared with $9.2 million, reflecting planned investments in the EXXUA launch.

Key points

  • Q4 fiscal 2026 net revenue was $16.1 million versus $15.1 million; EXXUA contributed $3.9 million and ADHD Portfolio revenue fell to $10.4 million from $13.1 million.
  • Full-year fiscal 2026 net revenue was $57.6 million versus $66.4 million, and full-year net loss was $14.3 million, or ($1.16) per share, versus $13.6 million, or ($2.16) per share.
  • Q4 Adjusted EBITDA was $0.5 million versus $2.0 million a year earlier; cash and cash equivalents were $26.3 million at June 30, 2026, compared with $31.0 million at June 30, 2025.
  • The company scheduled a conference call and webcast for September 22, 2026, at 4:30 p.m. Eastern time.

The filing

CompanyAYTU BIOPHARMA, INC (AYTU)
Form8-K, current report
Filed with the SECSep 22, 2026, 4:05 PM ET
Accession number0001437749-26-030900

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 22, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.